Last reviewed · How we verify
Plavix with Astrix
Plavix (clopidogrel) inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, reducing thrombotic events.
Plavix (clopidogrel) inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, reducing thrombotic events. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Secondary prevention of atherothrombotic events in patients with established peripheral arterial disease, previous myocardial infarction, or ischemic stroke.
At a glance
| Generic name | Plavix with Astrix |
|---|---|
| Sponsor | Seoul St. Mary's Hospital |
| Drug class | Antiplatelet agent (P2Y12 inhibitor) |
| Target | P2Y12 adenosine diphosphate receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine antiplatelet agent that irreversibly binds to the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. This mechanism reduces the formation of platelet-rich thrombi in arterial circulation. The combination with aspirin (Astrix) provides dual antiplatelet therapy for enhanced antithrombotic effect.
Approved indications
- Acute coronary syndrome (unstable angina, NSTEMI, STEMI)
- Secondary prevention of atherothrombotic events in patients with established peripheral arterial disease, previous myocardial infarction, or ischemic stroke
Common side effects
- Bleeding
- Dyspepsia
- Diarrhea
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- Cilostazol and Endothelial Progenitor Cell (PHASE4)
- Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation (PHASE4)
- Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin (PHASE4)
- Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study (PHASE3)
- Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plavix with Astrix CI brief — competitive landscape report
- Plavix with Astrix updates RSS · CI watch RSS
- Seoul St. Mary's Hospital portfolio CI